Atlas Trials

A Phase II Study of Gliadel, Concomitant Temozolomide and Radiation, Followed By Dose Dense Therapy With Temozolomide For Newly Diagnosed Malignant High Grade Glioma

Clinical trial NCT00660283 · UNKNOWN

Trial details

NCT number
NCT00660283
Sponsor
Kentuckiana Cancer Institute
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Glioma
Start date
2009-01-01
Primary completion
2010-12-01
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.